ClinicalTrials.gg
RecruitingNCT06487624Updated Apr 13, 2026

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

A Phase 1 interventional study of HCB301 in Advanced Solid Tumor and Refractory Hodgkin Lymphoma, sponsored by FBD Biologics Limited. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by FBD Biologics Limited · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hodgkin Disease with a site in China — 28 open to participants now, 31 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
35th of 53
50 · median 75
Started
2025
with 2 others
Phase 1
8 of 57
4 open now
Primary completion
2026-12
later than 19 of 30 live
Registered
48th of 57
by date

Among the 57 studies in Hodgkin Disease with a site in China, this one is the 35th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 19 of the 30 other live ones, and was the 48th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

28 of the 57 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Read the detailed description

This is a phase 1, open-label, multicenter, dose-escalation study. This study is to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and identification of maximum tolerated dose (MTD) of HCB301 intravenous injection in adults with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

Eligible subjects must have failed standard therapies, been intolerable, or been considered medically inappropriate by the investigator. Subjects will be treated until unacceptable AEs, radiographic or clinical documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study, whichever occurs first.

03

Conditions studied

  • Advanced Solid Tumor
  • Refractory Hodgkin Lymphoma

Keywords

  • Immunotherapy
  • CD47
  • PD-L1
  • TGF-beta
  • Tumor
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and be willing to sign the ICF.
  2. Male and female subjects of ≥18 years of age.
  3. Histologically/ confirmed, locally advanced solid tumor:

    subjects confirmed advanced solid tumors who have and should have no options for standard or approved therapies known to potentially confer clinical benefit or classical Hodgkin lymphoma, relapsed or refractory to at least 2 .

  4. For subjects with advanced solid tumors - must have at least 1 as defined by (RECIST) v1.1 at baseline.
  5. For subjects with classical Hodgkin lymphoma - must have classical Hodgkin lymphoma that is measurable or assessable for response.
  6. Must have performance status of 0 to 1 at Screening.
  7. Able to provide tumor tissue samples.
  8. Have a of ≥12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. With known history of to any components of HCB301.
  2. Known active or untreated and/or carcinomatous meningitis.
  3. Have undergone a major surgery or radical radiotherapy within 28 days or palliative radiotherapy within 14 days or have used a radioactive drug within 56 days prior to the first dose of HCB301.
  4. cardiovascular condition.
  5. Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia.
  6. With known inherited or acquired bleeding disorder or bleeding diathesis. .
  7. Have RBC transfusion within 4 weeks prior to Screening.
  8. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.
  9. Any or approved systemic cancer therapy administered within 21 days or 5 half-lives, whichever is shorter, before the first dose of the study drug.
  10. Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin ≤ 100 mg/QD.
  11. Have used herbal medication within 14 days prior to the first dose of HCB301.
  12. Have received any treatment targeting the SIRPα-7, , or TGF-β pathway.
  13. Have other requiring treatment within 2 years prior to the first dose of HCB301.
  14. An investigational device used within 28 days prior to the first dose of HCB301.
  15. Positive for , active infections, positive for , or known active or latent tuberculosis.
  16. Known to have a history of alcoholism or drug abuse.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental: 0.3 mg/kg HCB301

    0.3 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 0.6 mg/kg HCB301

    0.6 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 1.2 mg/kg HCB301

    1.2 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 2.4 mg/kg HCB301

    2.4 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 4.8 mg/kg HCB301

    4.8 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 9.6 mg/kg HCB301

    9.6 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

  • Experimental
    Experimental: 15.0 mg/kg HCB301

    15.0 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.

    Drug: HCB301

Interventions

  • DrugHCB301

    HCB301 administered via. intravenous (IV) infusion.

    Also known as: 2023-3979 Solid Tumors

06

What researchers measure

Primary outcomes

  1. Number/incidence and percentage of subjects with adverse events, including ADA.

    To evaluate the safety and tolerability of HCB301.

    Time frame: 12 months

  2. Number of subjects with MTD and RDE of HCB301.

    To determine the MTD and RDE.

    Time frame: 12 months

Secondary outcomes

  1. Overall Rate Response (ORR)

    ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR).

    Time frame: 12 months

  2. Duration of Response (DoR)

    DoR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD).

    Time frame: 12 months

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants who have a partial response (PR), critical response (CR), or disease stable (SD).

    Time frame: 12 months

  4. Progression-Free Survival (PFS)

    Defined as the duration from the start of treatment until tumor progression or death of any cause.

    Time frame: 12 months

  5. Peak Plasma Concentration (Cmax) of HCB301

    Peak Plasma Concentration (Cmax) of HCB301 following single and repeated IV doses of HCB301 at different dose levels.

    Time frame: 12 months

  6. Area under the plasma concentration versus time curve (AUC) of HCB301

    Area under the plasma concentration versus time curve (AUC) of HCB301 following single and repeated IV doses of HCB301 at different dose levels.

    Time frame: 12 months

  7. Time to maximum drug concentration in plasma (Tmax) of HCB301

    Time to maximum drug concentration in plasma (Tmax) of HCB301 following single and repeated IV doses of HCB301 at different dose levels.

    Time frame: 12 months

  8. Terminal elimination half-life (t1/2) of HCB301

    Terminal elimination half-life (t1/2) of HCB301 following single and repeated IV doses of HCB301 at different dose levels.

    Time frame: 12 months

Other outcomes

  1. CD47 receptor occupancy on circulating red blood cells (RBCs)

    CD47 receptor occupancy on circulating red blood cells (RBCs) will be measured as an indication of target engagement.

    Time frame: 12 months

  2. Concentration of potential PD biomarkers in participants will be assess.

    Changes in CD47 receptor occupancy on circulating CD3+ T cells and TGFβ1, 2, 3 will be assessed after HCB301 treatment.

    Time frame: 12 months

  3. ctDNA detection

    ctDNA detection in participants using next-generation sequencing (NGS ).

    Time frame: 12 months

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 91 phase 1 interventional studies under Hodgkin Disease, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 79. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jul 5, 2024
StartActual
Apr 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06487624
Lead sponsor
FBD Biologics Limited
Collaborators
HanchorBio Inc.
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Apr 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

FBD Clinical
Contact
HCB301-101@hanchorbio.com
+886-2-27921366

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion